Our various experiments have demonstrated that rituximab can significantly downregulate the expression of CD20 protein in DLBCL cells and further confirmed that PDK4 expression in DLBCL cells is associated with rituximab resistance. This evidence concerns the gene PDK4 and diffuse large B-cell lymphoma.